VX15-809-115: A Phase 3, 2-Part, Open-label Study to Evaluate the Safety and Pharmacokinetics of Lumacaftor/Ivacaftor Combination Therapy in Subjects Aged 2 through 5 Years With Cystic Fibrosis, Homozygous for the F508del CFTR

Project: Research project

Project Details

StatusFinished
Effective start/end date11/1/16 → 11/1/18

Funding

  • Vertex Pharmaceuticals Incorporated